Resverlogix Corp.
TSX : RVX

Resverlogix Corp.

July 21, 2005 12:47 ET

Resverlogix Corp. Launches NEXVAS'TM' Education Program

CALGARY, ALBERTA--(CCNMatthews - July 21, 2005) - Resverlogix Corp. (TSX:RVX), is pleased to announce that it has developed and launched a technical animation on its lead technology NEXVAS™. The animation will provide interested parties with an overview of how NEXVAS™ works. The animation describes the cardiovascular marketplace, underlying causes of atherosclerosis and the emerging role that ApoA1 enhancement technologies such as NEXVAS™ are expected to play in the future role of Cardiovascular Disease (CVD) management.

The complete animation presentation is now available for viewing and can be accessed at Resverlogix's website at www.resverlogix.com/nexvas-apoa1.htm

"The NEXVAS™ animation provides a wealth of market and scientific information in a quick and easy to understand format for our shareholders, investors and interested parties," stated Don McCaffrey, President and CEO of Resverlogix. "We trust that individuals who view the animation on our website will have a better understanding of how NEXVAS™ works and further understand its promising potential in CVD."

"As this cutting edge field in biotechnology had limited information to the public we took the initiative to build a communication platform that illustrates the important cardio-protective role of ApoA1 in reducing atherosclerosis and how our lead technology is positioned in this important emerging health market segment" acknowledged Kenneth Lebioda, Vice President of Business & Market Development at Resverlogix.

About Resverlogix Corp.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology program NEXVAS™ applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases. The Corporation's second technology program TGF-Beta Shield™ utilizes an adoptive immunotherapy approach to target cancers and fibrotic diseases. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for significant markets with unmet medical need. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.


This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Exchange does not except responsibility for the adequacy or accuracy of this news release.

Contact Information

  • Resverlogix Corp.
    Donald J. McCaffrey
    President/CEO
    (403) 254-9252 ext. 223
    (403) 256-8495 (FAX)
    Email: don@resverlogix.com
    or
    Resverlogix Corp.
    Kenneth E. Lebioda
    VP Business & Market Development
    (403) 254-9252 ext. 227
    (403) 256-8495 (FAX)
    Email: ken@resverlogix.com
    Website: www.resverlogix.com